Press release
Marginal Zone Lymphoma Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential
DelveInsight's "Marginal Zone Lymphoma Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Download DelveInsight's comprehensive Marginal Zone Lymphoma Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Marginal Zone Lymphoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Marginal Zone Lymphoma Pipeline Report
* On 03 September 2025, Genmab announced a clinical trial to determine the maximum tolerated dose (MTD) and the recommended Phase-2 dose (RP2D), as well as to establish the safety profile of epcoritamab in Japanese participants with relapsed, progressive, or refractory B-cell lymphoma and Japanese participants with B-cell lymphomas that have achieved PR or CR.
* On 03 September 2025, Galapagos NV conducted a study is evaluate whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use. A study continues with the dose expansion phase. Different doses deemed safe by the SRC within the same indication may be explored in the dose-expansion phase to help select the optimal dose for further development.
* DelveInsight's Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Marginal Zone Lymphoma treatment.
* The leading Marginal Zone Lymphoma Companies such as Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
* Promising Marginal Zone Lymphoma Therapies such as Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 g/Kg, Copanlisib, Rituximab, Venetoclax , and others.
Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Marginal Zone Lymphoma Clinical Trials and Studies [https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Marginal Zone Lymphoma Emerging Drugs
* Tafasitamab: Incyte Corporation
Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb Registered engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. The therapy is currently in Phase III stage of clinical trial evaluation to treat Marginal Zone Lymphoma.
* Amdizalisib (HMPL-689): HUTCHMED
The investigational drug candidate amdizalisib is a novel, selective small molecule inhibitor targeting the isoform phosphoinositide 3'-kinase delta (PI3K), a key component in the B-cell receptor signaling pathway. We have designed amdizalisib with increased PI3K isoform selectivity. Amdizalisib's pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. Amdizalisib is being investigated in studies in the U.S., Europe, China and Australia in various subtypes of advanced relapsed or refractory non-Hodgkin's lymphoma, including follicular lymphoma and marginal zone lymphoma.
* Orelabrutinib: InnoCare Pharma
Orelabrutinib is a small molecule Bruton's tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases. In the field of oncology, InnoCare received approval for orelabrutinib from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (R/R SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Currently, it is in Phase II stage of clinical trial evaluation to treat Marginal Zone Lymphoma (MZL).
* EO2463: Enterome
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. EO2463 is designed to trigger the immune system into recognizing B cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes that cause NHL.
The Marginal Zone Lymphoma pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
* Marginal Zone Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.
Get a detailed analysis of the latest innovations in the Marginal Zone Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Marginal Zone Lymphoma Unmet Needs [https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Marginal Zone Lymphoma Companies
Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Marginal Zone Lymphoma Products have been categorized under various Molecule types such as
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
Download DelveInsight's latest report to gain strategic insights into upcoming Marginal Zone Lymphoma Therapies and key drugs developments @ Marginal Zone Lymphoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Marginal Zone Lymphoma Pipeline Report
* Coverage- Global
* Marginal Zone Lymphoma Companies- Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
* Marginal Zone Lymphoma Therapies- Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 g/Kg, Copanlisib, Rituximab, Venetoclax , and others.
* Marginal Zone Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Marginal Zone Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find out in DelveInsight's exclusive pipeline report-access it now! @ Marginal Zone Lymphoma Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Marginal Zone Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Marginal Zone Lymphoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Tafasitamab: Incyte Corporation
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Orelabrutinib: InnoCare Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* EO2463: Enterome
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Marginal Zone Lymphoma Key Companies
* Marginal Zone Lymphoma Key Products
* Marginal Zone Lymphoma- Unmet Needs
* Marginal Zone Lymphoma- Market Drivers and Barriers
* Marginal Zone Lymphoma- Future Perspectives and Conclusion
* Marginal Zone Lymphoma Analyst Views
* Marginal Zone Lymphoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=marginal-zone-lymphoma-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/marginal-zone-lymphoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Marginal Zone Lymphoma Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential here
News-ID: 4174535 • Views: …
More Releases from ABNewswire

Rheumatoid Arthritis Pipeline Outlook 2025: Insights Into Therapies, Research, a …
DelveInsight's, "Rheumatoid Arthritis Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Rheumatoid Arthritis (RA) pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and…

B-Cell Non-Hodgkin Lymphoma Pipeline Outlook 2025: Insights Into Therapies, Rese …
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the B-Cell Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Non-Hodgkin Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive B-cell non-Hodgkin Lymphoma pipeline products in this…

Small Lymphocytic Lymphoma Pipeline Outlook 2025: Insights Into Therapies, Resea …
DelveInsight's, "Small Lymphocytic Lymphoma Pipeline Insight, 2025" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the Small Lymphocytic Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Lymphocytic Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Dive into…

Frontotemporal Dementia Pipeline Outlook 2025: Insights Into Therapies, Research …
DelveInsight's, "Frontotemporal Dementia Pipeline Insight 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Frontotemporal Dementia pipeline landscape. It covers the Frontotemporal Dementia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Frontotemporal Dementia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in…
More Releases for Marginal
Marginal-lubricating Bearings Market to Witness Robust Expansion by 2025
The latest research report"Global Marginal-lubricating Bearings Market Growth 2025-2031" studied by LP Information offers a comprehensive overview of theMarginal-lubricating Bearings market, providing insights into its drivers, restraints, and future trends. This study employs both primary and secondary research methods to offer unbiased perspectives on the globalMarginal-lubricating Bearings industry, assisting decision-makers in making informed business choices.
The research employs Porter's Five Forces analysis and SWOT analysis to offer a clear understanding…
Marginal Zone Lymphoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Marginal Zone Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key…
Auto Injector Market In-Depth Analysis & Marginal Revenue Growth
An autoinjector (or auto-injector) is a medical device designed to deliver a dose of a particular drug. The injectors were initially designed to overcome the hesitation associated with self-administration of the needle-based drug delivery device.
Most autoinjectors are one-use, disposable, spring-loaded syringes. By design, autoinjectors are easy to use and are intended for self-administration by patients, or administration by untrained personnel. The site of injection depends on the drug loaded,…
Latest Trends in Marginal Zone Lymphoma Treatment Market 2020-2025
Market Overview
The Marginal Zone Lymphoma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations during COVID-19 outbreak.
Market segmentation
Marginal Zone Lymphoma Treatment market is split by Type and Application. For…
A2P SMS Market Cost Profit and Marginal Revenue Analysis by 2026
In this Report Titled Global A2P SMS Market Growth (Status and Outlook) 2019-2026 the latest data has been delivered, along with collection of realistic information, quantitative and qualitative estimation by industry experts, and the contribution from industry associates across the value chain. This report is a vast research database spread across various pages with numerous tables, charts, and figures in it. This report presents a close watch on the dominating…
Baking Fats Market In-Depth Analysis & Marginal Revenue Growth 2020-2026
How will be investment trends and competition in the global Baking Fats market during forecast period 2020-2026? Get the detail insights from QY Research.
Los Angeles, United State, February 2020: The report is just the right resource that global and regional Baking Fats players and investors need to peep into the future of their business and plan out effective growth strategies. It is a compilation of intelligent and accurate research and…